{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:44Z","timestamp":1793239424482,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Ment Health Syst"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Understanding drug market dynamics and their underlying driving factors is paramount to developing effective responses to the overdose crisis in North America. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug market trajectories. The emergence of fentanyl on North American street markets from 2014 onwards led to a shift of street drug use patterns. Previously perceived as contaminants, novel synthetic opioids became the drugs of choice and a trend towards higher potency was observed across various substance classes. The diversification of distribution strategies as well as the regionalisation and industrialisation of production followed basic economic principles that were heavily influenced by prosecution and policy makers. Particularly, the trend towards higher potency is likely most indicative of what to expect from future illicit drug market developments. Nitazenes and fentanyl-analogues, several times more potent than fentanyl itself, are increasingly detected in toxicological testing and have the potential of becoming the drugs of choice in the future. The dynamic of drug import and local production is less clear and influenced by a multitude of factors like precursor availability, know-how, infrastructure, and the success of local drug enforcement strategies. Drug market dynamics and the current trajectory towards ultrapotent opioids need to be recognised by legislation, enforcement, and the health care system to prepare effective responses. Without significant improvements in treatment access, the implementation of preventative approaches and early warning systems, the mortality rate will continue to increase. Furthermore, there is no mechanism in place preventing the currently North American focused overdose crisis to spread to other parts of the globe, particularly Europe. A system of oversight, research, and treatment is needed to address mortality rates of historic proportions and prevent further harm.<\/jats:p>","DOI":"10.1186\/s13033-023-00601-x","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T04:02:06Z","timestamp":1698206526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Shifting drug markets in North America - a global crisis in the making?"],"prefix":"10.1186","volume":"17","author":[{"given":"Maximilian","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean N.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickie","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undine E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"601_CR1","doi-asserted-by":"publisher","first-page":"n2865","DOI":"10.1136\/bmj.n2865","volume":"375","author":"O Dyer","year":"2021","unstructured":"Dyer O. A record 100 000 people in the US died from overdoses in 12 months of the pandemic, says CDC. BMJ. 2021;375:n2865.","journal-title":"BMJ"},{"key":"601_CR2","unstructured":"Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics [Internet]. 2021 [cited 2023 Jan 24]. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"issue":"1","key":"601_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13033-021-00512-9","volume":"15","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Mathew N, Budd G, Wong JSH, Tsang VWL, et al. Shifting north american drug markets and challenges for the system of care. Int J Ment Health Syst. 2021;15(1):1\u20138.","journal-title":"Int J Ment Health Syst"},{"issue":"2","key":"601_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bph.14860","volume":"177","author":"R Hill","year":"2020","unstructured":"Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol. 2020;177(2):254.","journal-title":"Br J Pharmacol"},{"issue":"10324","key":"601_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","volume":"399","author":"K Humphreys","year":"2022","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford\u2013Lancet Commission. Lancet. 2022;399(10324):555\u2013604.","journal-title":"Lancet"},{"issue":"4","key":"601_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","volume":"34","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021;34(4):405\u201312.","journal-title":"Curr Opin Psychiatry"},{"key":"601_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users\u2019 perceptions of fentanyl-adulterated and -substituted \u2018heroin\u2019. Int J Drug Policy. 2017;46:146.","journal-title":"Int J Drug Policy"},{"key":"601_CR8","unstructured":"News. April 2019 \u2013 China: Announcement to place all fentanyl-related substances under national control [Internet]. [cited 2022 Sep 3]. Available from: https:\/\/www.unodc.org\/LSS\/announcement\/Details\/f2adea68-fbed-4292-a4cc-63771c943318."},{"key":"601_CR9","unstructured":"UNODC. Global Synthetic Drug Assessment \u2013 Regional Overview Americas. 2020."},{"key":"601_CR10","doi-asserted-by":"publisher","first-page":"103574","DOI":"10.1016\/j.drugpo.2021.103574","volume":"101","author":"M Ferguson","year":"2022","unstructured":"Ferguson M, Parmar A, Papamihali K, Weng A, Lock K, Buxton JA. Investigating opioid preference to inform safe supply services: a cross sectional study. Int J Drug Policy. 2022;101:103574.","journal-title":"Int J Drug Policy"},{"key":"601_CR11","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.drugpo.2020.102665","volume":"77","author":"M Karamouzian","year":"2020","unstructured":"Karamouzian M, Papamihali K, Graham B, Crabtree A, Mill C, Kuo M, et al. Known fentanyl use among clients of harm reduction sites in British Columbia, Canada. Int J Drug Policy. 2020;77:102665.","journal-title":"Int J Drug Policy"},{"key":"601_CR12","unstructured":"Statistical Bulletin. 2022 \u2014 seizures of drugs | www.emcdda.europa.eu [Internet]. [cited 2022 Nov 29]. Available from: https:\/\/www.emcdda.europa.eu\/data\/stats2022\/szr_en."},{"key":"601_CR13","unstructured":"Centers for Disease Control and Prevention. Synthetic Opioid Overdose Data | Drug Overdose | CDC Injury Center [Internet]. 2022 [cited 2022 Aug 27]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/deaths\/synthetic\/index.html."},{"key":"601_CR14","unstructured":"British Columbia Coroners Service. Illicit Drug Toxicity Deaths in BC [Internet]. 2023 [cited 2022 Feb 26]. Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/life-events\/death\/coroners-service\/statistical-reports."},{"key":"601_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","volume":"171","author":"J Suzuki","year":"2017","unstructured":"Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"601_CR16","doi-asserted-by":"crossref","unstructured":"Montanari E, Madeo G, Pichini S, Busard\u00f2 FP, Carlier J. Acute intoxications and fatalities Associated with Benzimidazole Opioid (Nitazene Analog) Use: a systematic review. Ther Drug Monit. 2022.","DOI":"10.1097\/FTD.0000000000000970"},{"issue":"9","key":"601_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2215-0366(22)00241-3","volume":"9","author":"RM Krausz","year":"2022","unstructured":"Krausz RM, Westenberg JN, Meyer M, Choi F. The upcoming synthetic ultrapotent opioid wave as a foreseeable disaster. Lancet Psychiatry. 2022;9(9):699\u2013700.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"601_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","volume":"96","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Krotulski AJ, Walther D, Glatfelter GC, Papsun D, Walton SE, et al. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole \u2018nitazene\u2019 synthetic opioid. Arch Toxicol. 2022;96(6):1845\u201363.","journal-title":"Arch Toxicol"},{"key":"601_CR19","unstructured":"Government of Canada. Health Canada Drug Analysis Service, Royal Canadian Mounted Police, Canada Border Services Agency. At-A-Glance: The Emergence of Nitazenes and Brorphine in Canada since 2019. Longueuil (QC) [Internet]. 2022 [cited 2022 Aug 27]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/emergence-nitazenes-brorphine-canada-2019.html."},{"issue":"6","key":"601_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00204-022-03257-7","volume":"96","author":"MF Fogarty","year":"2022","unstructured":"Fogarty MF, Vandeputte MM, Krotulski AJ, Papsun D, Walton SE, Stove CP, et al. Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238. Arch Toxicol. 2022;96(6):1701\u201310.","journal-title":"Arch Toxicol"},{"key":"601_CR21","unstructured":"EMCDDA. Synthetic cannabinoids in Europe - a review [Internet]. 2021 [cited 2022 Aug 27]. Available from: www.emcdda.europa.eu."},{"key":"601_CR22","unstructured":"EMCDDA. European Drug Report - Trends and Developments [Internet]. 2022 [cited 2022 Aug 28]. Available from: www.emcdda.europa.eu."},{"issue":"6","key":"601_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/dta.2786","volume":"12","author":"S Halter","year":"2020","unstructured":"Halter S, Haschimi B, Mogler L, Auw\u00e4rter V. Impact of legislation on NPS markets in Germany \u2013 The rise and fall of 5F-ADB. Drug Test Anal. 2020;12(6):853\u20136.","journal-title":"Drug Test Anal"},{"issue":"2","key":"601_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","volume":"39","author":"KA Seely","year":"2012","unstructured":"Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234\u201343.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"601_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jat\/bkz092","volume":"44","author":"JA Hvozdovich","year":"2020","unstructured":"Hvozdovich JA, Chronister CW, Logan BK, Goldberger BA. Case Report: synthetic cannabinoid deaths in state of Florida Prisoners. J Anal Toxicol. 2020;44(3):298\u2013300.","journal-title":"J Anal Toxicol"},{"issue":"4","key":"601_CR26","first-page":"342","volume":"41","author":"P Thirakul","year":"2017","unstructured":"Thirakul P, Hair LS, Bergen KL, Pearson JM. Clinical presentation, autopsy results and toxicology findings in an Acute N-Ethylpentylone Fatality. J Anal Toxicol. 2017;41(4):342\u20136.","journal-title":"J Anal Toxicol"},{"key":"601_CR27","unstructured":"China\u2019s Role in Illicit Fentanyl Running Rampant on US Streets. - Congressman David Trone [Internet]. [cited 2023 Feb 22]. Available from: https:\/\/trone.house.gov\/2023\/01\/08\/chinas-role-in-illicit-fentanyl-running-rampant-on-us-streets\/."},{"key":"601_CR28","unstructured":"Multi-jurisdictional investigation results. in major fentanyl seizure | BC Gov News [Internet]. [cited 2023 Feb 22]. Available from: https:\/\/news.gov.bc.ca\/stories\/multi-jurisdictional-investigation-results-in-major-fentanyl-seizure."},{"key":"601_CR29","unstructured":"BC RCMP - BC RCMP Federal Policing prevents. 27 million doses of potentially lethal fentanyl from hitting the streets [Internet]. [cited 2023 Feb 22]. Available from: https:\/\/bc-cb.rcmp-grc.gc.ca\/ViewPage.action?siteNodeId=2087&languageId=1&contentId=78093."},{"key":"601_CR30","unstructured":"Royal Canadian Mounted Police. ; Massive drug lab bust highlights coordinated approach to gangs and organized crime [Internet]. [cited 2023 Jan 15]. Available from: https:\/\/bc-cb.rcmp-grc.gc.ca\/ViewPage.action?siteNodeId=2126&languageId=1&contentId=69480."},{"key":"601_CR31","doi-asserted-by":"crossref","unstructured":"Babor TF, Caulkins J, Fischer B, Foxcroft D, Humphreys K, Medina-Mora ME et al. Illegal markets: the economics and social costs of drug distribution. 2018 Aug 23 [cited 2022 Sep 3];1. Available from: https:\/\/academic.oup.com\/book\/27471\/chapter\/197372620.","DOI":"10.1093\/oso\/9780198818014.003.0005"},{"key":"601_CR32","unstructured":"U.S. Customs and Border Protection. Drug Seizure Statistics [Internet]. 2022. [cited 2022 Aug 28]. Available from: https:\/\/www.cbp.gov\/newsroom\/stats\/drug-seizure-statistics."},{"key":"601_CR33","unstructured":"British Columbia Coroners Service. Illicit Drug Toxicity Deaths in BC - Knowledge Update: Mode of consumption [Internet]. 2022 [cited 2022 Nov 9]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/mode-of-consumption.pdf."},{"key":"601_CR34","unstructured":"UNODC. In Focus: Trafficking over the Darknet - World Drug Report 2020. 2020 [cited 2022 Sep 10]; Available from: www.unodc.org\/wdr2020."},{"issue":"1","key":"601_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00204-013-1163-9","volume":"88","author":"MJ Valente","year":"2014","unstructured":"Valente MJ, De Guedes P, De Lourdes Bastos M, Carvalho F, Carvalho M. Khat and synthetic cathinones: a review. Arch Toxicol. 2014;88(1):15\u201345.","journal-title":"Arch Toxicol"},{"issue":"4","key":"601_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.mcna.2018.02.010","volume":"102","author":"R Graddy","year":"2018","unstructured":"Graddy R, Buresh ME, Rastegar DA. New and Emerging Illicit psychoactive substances. Med Clin North Am. 2018;102(4):697\u2013714.","journal-title":"Med Clin North Am"},{"issue":"9","key":"601_CR37","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.amjmed.2012.02.019","volume":"125","author":"EA Ross","year":"2012","unstructured":"Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive bath salts intoxication with methylenedioxypyrovalerone. Am J Med. 2012;125(9):854\u20138.","journal-title":"Am J Med"},{"issue":"1","key":"601_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamapsychiatry.2021.3292","volume":"79","author":"B Pardo","year":"2022","unstructured":"Pardo B. Insights into mixing fentanyl and benzodiazepines from canadian drug seizures. JAMA Psychiatry. 2022;79(1):81\u20133.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"601_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/dar.13052","volume":"39","author":"S Nielsen","year":"2020","unstructured":"Nielsen S, McAuley A, Etizolam. A rapid review on pharmacology, non-medical use and harms. Drug Alcohol Rev. 2020;39(4):330\u20136.","journal-title":"Drug Alcohol Rev"},{"key":"601_CR40","unstructured":"Government of Canada. Drug Analysis Service - Analyzed Drug Report - July to September 2022 [Internet]. 2023 [cited 2023 Feb 26]. Available from: https:\/\/health-infobase.canada.ca\/drug-analysis-service\/analyzed-drug-report.html."},{"key":"601_CR41","unstructured":"U.S. Department of Justice. ; The Growing Threat of Xylazine and its Mixture with Illicit Drugs - DEA Joint Intelligence Report. 2022."},{"key":"601_CR42","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380.","journal-title":"Drug Alcohol Depend"},{"key":"601_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Col\u00f3n","year":"2014","unstructured":"Ruiz-Col\u00f3n K, Chavez-Arias C, D\u00edaz-Alcal\u00e1 JE, Mart\u00ednez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1\u20138.","journal-title":"Forensic Sci Int"},{"key":"601_CR44","doi-asserted-by":"publisher","unstructured":"Kertesz SG, Gordon AJ. A crisis of opioids and the limits of prescription control: United States. Addiction [Internet]. 2019 Jan 1 [cited 2023 Aug 29];114(1):169\u201380. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/add.14394.","DOI":"10.1111\/add.14394"},{"issue":"2","key":"601_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","volume":"50","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Sold as Heroin: perceptions and use of an Evolving Drug in Baltimore, MD. J Psychoact Drugs. 2018;50(2):167.","journal-title":"J Psychoact Drugs"},{"key":"601_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today\u2019s fentanyl crisis: prohibition\u2019s Iron Law, revisited. Int J Drug Policy. 2017;46:156\u20139.","journal-title":"Int J Drug Policy"},{"key":"601_CR47","unstructured":"Fentanyl warning following Australia\u2019. s largest detection of deadly opioid | Australian Federal Police [Internet]. [cited 2023 Feb 25]. Available from: https:\/\/www.afp.gov.au\/news-media\/media-releases\/fentanyl-warning-following-australia%E2%80%99s-largest-detection-deadly-opioid."},{"issue":"4","key":"601_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0706743721993634","volume":"66","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Wong JSH, Westenberg JN, Choi F, Sch\u00fctz CG, Jang KL. Canada\u2019s response to the dual public health crises: a cautionary tale. Can J Psychiatry. 2021;66(4):349\u201353.","journal-title":"Can J Psychiatry"},{"key":"601_CR49","unstructured":"B.C. receives exemption to decriminalize possession of some illegal drugs for personal use | BC Gov News [Internet]. [cited 2022 Sep 4]. Available from: https:\/\/news.gov.bc.ca\/releases\/2022MMHA0029-000850."},{"key":"601_CR50","doi-asserted-by":"crossref","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF et al. Opioid use disorder. Nature Reviews Disease Primers 2020 6:1. 2020;6(1):1\u201328.","DOI":"10.1038\/s41572-019-0137-5"},{"issue":"3","key":"601_CR51","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of Medication for Opioid Use Disorder among US adolescents and adults with need for Opioid Treatment, 2019. JAMA Netw Open. 2022;5(3):e223821\u20131.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"601_CR52","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","volume":"34","author":"AW Dick","year":"2015","unstructured":"Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34(6):1028\u201334.","journal-title":"Health Aff"},{"issue":"7","key":"601_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after Federal Oversight. Can J Psychiatry. 2017;62(7):444\u201350.","journal-title":"Can J Psychiatry"},{"issue":"12","key":"601_CR54","doi-asserted-by":"publisher","first-page":"e0226349","DOI":"10.1371\/journal.pone.0226349","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang JC, Roman-Urrestarazu A, Brayne C. Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17. PLoS ONE. 2019;14(12):e0226349.","journal-title":"PLoS ONE"},{"issue":"10","key":"601_CR55","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","volume":"38","author":"M Vogel","year":"2013","unstructured":"Vogel M, Kn\u00f6pfli B, Schmid O, Prica M, Strasser J, Prieto L, et al. Treatment or high: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477\u201384.","journal-title":"Addict Behav"},{"key":"601_CR56","doi-asserted-by":"publisher","unstructured":"Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T et al. One size does not fit all\u2014evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction [Internet]. 2019 Jan 1 [cited 2023 Aug 29];114(1):103\u201311. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/add.14442.","DOI":"10.1111\/add.14442"},{"issue":"1","key":"601_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1360-0443.2009.02741.x","volume":"105","author":"A Uchtenhagen","year":"2010","unstructured":"Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29\u201337.","journal-title":"Addiction"},{"issue":"1","key":"601_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00358-x","volume":"16","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1):1\u20137.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"601_CR59","doi-asserted-by":"publisher","first-page":"103548","DOI":"10.1016\/j.drugpo.2021.103548","volume":"101","author":"M Meyer","year":"2022","unstructured":"Meyer M, Strasser J, K\u00f6ck P, Walter M, Vogel M, D\u00fcrsteler KM. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic\u2013Is an update of legal restrictions warranted? Int J Drug Policy. 2022;101:103548.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"601_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-022-00644-2","volume":"19","author":"M Meyer","year":"2022","unstructured":"Meyer M, Westenberg JN, Strasser J, D\u00fcrsteler KM, Lang UE, Krausz M, et al. Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment. Harm Reduct J. 2022;19(1):1\u20136.","journal-title":"Harm Reduct J"},{"issue":"1","key":"601_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-023-00731-y","volume":"20","author":"M Vogel","year":"2023","unstructured":"Vogel M, Meyer M, Westenberg JN, Kormann A, Simon O, Salim Hassan Fadlelseed R, et al. Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a swiss multicentre observational study. Harm Reduct J. 2023;20(1):1\u20138.","journal-title":"Harm Reduct J"},{"key":"601_CR62","doi-asserted-by":"crossref","unstructured":"Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment. The Lancet Psychiatry. Volume 9. Elsevier; 2022. pp. 103\u20135.","DOI":"10.1016\/S2215-0366(21)00393-X"},{"key":"601_CR63","doi-asserted-by":"crossref","unstructured":"Meyer M, Westenberg JN, Krausz RM. The Fentanyl System shock \u2013 are there Lessons to learn from the COVID-19 System Shock Framework? Comment on the COVID-19 System Shock Framework: capturing Health System Innovation during the COVID-19 pandemic. Int J Health Policy Manag. 2023.","DOI":"10.34172\/ijhpm.2023.7409"},{"key":"601_CR64","unstructured":"Safer supply. : Prescribed medications as a safer alternative to toxic illegal drugs - Canada.ca [Internet]. [cited 2022 Nov 19]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply.html."},{"key":"601_CR65","unstructured":"Public Health Agency of Canada. ; Apparent Opioid and Stimulant Toxicity Deaths - Surveillance of Opioid- and Stimulant-Related Harms in Canada. 2022."},{"key":"601_CR66","doi-asserted-by":"publisher","first-page":"103976","DOI":"10.1016\/j.drugpo.2023.103976","volume":"113","author":"O Price","year":"2023","unstructured":"Price O, Man N, Sutherland R, Bruno R, Dietze P, Salom C, et al. Disruption to australian heroin, methamphetamine, cocaine and ecstasy markets with the COVID-19 pandemic and associated restrictions. Int J Drug Policy. 2023;113:103976.","journal-title":"Int J Drug Policy"}],"container-title":["International Journal of Mental Health Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13033-023-00601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13033-023-00601-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13033-023-00601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:29:00Z","timestamp":1700350140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmhs.biomedcentral.com\/articles\/10.1186\/s13033-023-00601-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1186\/s13033-023-00601-x","relation":{},"ISSN":["1752-4458"],"issn-type":[{"value":"1752-4458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MV has received consultation fees from Camurus. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}